Skip to main content

Candel Therapeutics, Inc.

corporate_fare Company Profile

Candel Therapeutics, Inc.

CADL·NASDAQ·Life Sciences·CIK 0001841387

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops off-the-shelf viral immunotherapies to generate an individualized, systemic anti-tumor immune response in cancer patients. The company's engineered viruses aim to induce immunogenic cell death within the tumor microenvironment, releasing tumor neo-antigens and creating a pro-inflammatory environment at the injection site. This process is intended to lead to in-situ immunization against the injected tumor and distant metastases. Local administration is designed to achieve these effects while minimizing systemic exposure and toxicity. The immune cells induced by these therapies are believed to target specific tumor antigens, potentially improving responses in immunologically "hot" tumors and transforming non-inflamed "cold" tumors into "hot" tumors. While product candidates are administered directly into the tumor, preclinical studies and clinical trials have shown systemic immune responses, suggesting the potential for an "abscopal" effect against distal, uninjected tumors. Candel Therapeutics has established two clinical off-the-shelf viral immunotherapy platforms using genetically modified adenovirus and herpes simplex virus (HSV) constructs. Its most advanced product candidate, aglatimagene besadenovec (aglatimagene, previously CAN-2409), is an off-the-shelf adenovirus product candidate administered with the prodrug valacyclovir, which has shown promising clinical activity across various solid tumor indications.

Candel Therapeutics, Inc. (NASDAQ:CADL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for CADL at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Director Paul Manning Buys Nearly $3M in Candel Therapeutics Stock
  • Candel Therapeutics Formalizes $100M Public Offering, Extends Cash Runway to Q1 2028
  • Candel Therapeutics Finalizes $100M Public Offering, Extending Cash Runway for Key Programs
  • Candel Therapeutics Announces $100 Million Common Stock Offering, Extending Cash Runway to Q1 2028
  • Candel Therapeutics Secures $100M Royalty Funding from RTW for CAN-2409 Prostate Cancer Launch

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$38.18M
Diluted EPS
-$0.72
Op. Cash Flow
-$38.31M
Free Cash Flow
-$38.9M
Operating Income
-$48.27M
Cash & Equivalents
$119.73M
Total Debt
$46.12M
Debt / Equity
0.89×
Shares Outstanding
54.9M sh
Source: 10-K · filed 2026-03-12 · accession 0001193125-26-103134
$4.99 -0.97% today
52-week range · as of 2026-11-12 $4.35 – $14
Market cap
$395.37M
Volume
1.7M (1.2× avg)
3-mo avg 1.4M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CADL - Filings & News (Page 2)

CADL
Feb 26, 2026, 7:38 PM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $5.69
Real-time Price: $4.99 info
Change: -$0.6975 (-12%) info
Market Cap: $395.368M info
CADL
Feb 23, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.10
Real-time Price: $4.99 info
Change: -$0.1088 (-2%) info
Market Cap: $395.368M info
CADL
Feb 20, 2026, 4:16 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $5.07
Real-time Price: $4.99 info
Change: -$0.0787 (-2%) info
Market Cap: $395.368M info
CADL
Feb 19, 2026, 4:31 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $5.46
Real-time Price: $4.99 info
Change: -$0.4688 (-9%) info
Market Cap: $395.368M info
CADL
Feb 19, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.15
Real-time Price: $4.99 info
Change: -$1.16 (-19%) info
Market Cap: $395.368M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets